OncoC4

Executive Summary

OncoC4 is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class antibody-based therapies for hard-to-treat cancers and Alzheimer's disease. Founded in 2015 and headquartered in Rockville, Maryland, the company leverages innate and adaptive immune checkpoints, including CTLA-4, PD-1/VEGF, CD24, and Siglec pathways, to design novel immunotherapies. Its lead program, ONC-392 (anti-CTLA-4), is in Phase 1/2 trials for solid tumors, while a PD-1/VEGF bispecific antibody and anti-CD24/Siglec candidates are in preclinical or early clinical development. OncoC4's approach aims to overcome resistance mechanisms and broaden the therapeutic window of immune checkpoint inhibitors.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data readout for ONC-392 (anti-CTLA-4) in solid tumors70% success
• Q4 2026FDA IND clearance for anti-CD24 antibody in Alzheimer's disease50% success
• TBDPotential partnership or licensing deal for PD-1/VEGF bispecific40% success